Cargando…

Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A

Merkel cell carcinomas (MCCs) are rare, aggressive, cutaneous neuroendocrine tumours, approximately 80% of which are caused by the genomic integration of Merkel cell polyomavirus (MCPyV). MCPyV-positive MCCs carry poor prognosis in approximately 70% of cases, highlighting the need for greater unders...

Descripción completa

Detalles Bibliográficos
Autores principales: Guadagni, Stefano, Farina, Antonietta Rosella, Cappabianca, Lucia Annamaria, Sebastiano, Michela, Maccarone, Rita, Zelli, Veronica, Clementi, Marco, Chiominto, Alessandro, Bruera, Gemma, Ricevuto, Enrico, Fiorentini, Giammaria, Sarti, Donatella, Mackay, Andrew Reay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662965/
https://www.ncbi.nlm.nih.gov/pubmed/33153070
http://dx.doi.org/10.3390/ijms21218222
_version_ 1783609517223706624
author Guadagni, Stefano
Farina, Antonietta Rosella
Cappabianca, Lucia Annamaria
Sebastiano, Michela
Maccarone, Rita
Zelli, Veronica
Clementi, Marco
Chiominto, Alessandro
Bruera, Gemma
Ricevuto, Enrico
Fiorentini, Giammaria
Sarti, Donatella
Mackay, Andrew Reay
author_facet Guadagni, Stefano
Farina, Antonietta Rosella
Cappabianca, Lucia Annamaria
Sebastiano, Michela
Maccarone, Rita
Zelli, Veronica
Clementi, Marco
Chiominto, Alessandro
Bruera, Gemma
Ricevuto, Enrico
Fiorentini, Giammaria
Sarti, Donatella
Mackay, Andrew Reay
author_sort Guadagni, Stefano
collection PubMed
description Merkel cell carcinomas (MCCs) are rare, aggressive, cutaneous neuroendocrine tumours, approximately 80% of which are caused by the genomic integration of Merkel cell polyomavirus (MCPyV). MCPyV-positive MCCs carry poor prognosis in approximately 70% of cases, highlighting the need for greater understanding of the oncogenic mechanisms involved in pathogenesis, progression and post-therapeutic relapse, and translation into novel therapeutic strategies. In a previous pilot study, we reported a potential relationship between MCPyV gene expression and oncogenic alternative Δ exon 6–7 TrkAIII splicing in formalin-fixed paraffin-embedded (FFPE) MCC tissues from a 12-patient cohort of >90% MCPyV-positive MCCs, diagnosed at San Salvatore Hospital, L’Aquila, Italy, characterising a new MCC subgroup and unveiling a novel potential MCPyV oncogenic mechanism and therapeutic target. This, however, could not be fully verified due to poor RNA quality and difficulty in protein extraction from FFPE tissues. Here, therefore, we extend our previous observations to confirm the relationship between MCPyV and oncogenic alternative Δ exon 6–7 TrkAIII splicing in fresh, nonfixed, MCPyV-positive MCC metastasis by detecting sequence-verified RT-PCR products, including full-length Δ exon 6–7 TrkAIII, and by Western blot detection of a 100 kDa TrkA protein isoform of identical size to 100 kDa Δ exon 6–7 TrkAIII expressed by stable transfected SH-SY5Y cells. We also report that in three MCC patients submitted for multidisciplinary treatment, including locoregional chemotherapy, MCPyV large T-antigen mRNA expression, Δ exon 6–7 TrkAIII mRNA expression and intracellular indirect immunofluorescence (IF) TrkA and phosphorylation protein isoform(s) immunoreactivity in FFPE tissues were not reduced in postchemotherapeutic-relapsed MCCs compared to pretherapeutic MCCs, extending the possible roles of this novel potential MCPyV oncogenic mechanism from MCC pathogenesis to post-therapeutic relapse and progression. Detection of alternative Δ exon 6–7 TrkAIII splicing in MCC, therefore, not only characterises a new MCPyV-positive MCC subgroup and unveils a novel potential MCPyV oncogenic mechanism but also identifies patients who may benefit from inhibitors of MCPyV T-antigen and/or TrkAIII expression or clinically approved Trk kinase inhibitors such as larotrectinib or entrectinib, which are known to inhibit activated TrkA oncogenes and to elicit durable responses in TrkA-fusion oncogene-driven cancers, supporting the call for a large-scale multicentre clinical study.
format Online
Article
Text
id pubmed-7662965
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76629652020-11-14 Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A Guadagni, Stefano Farina, Antonietta Rosella Cappabianca, Lucia Annamaria Sebastiano, Michela Maccarone, Rita Zelli, Veronica Clementi, Marco Chiominto, Alessandro Bruera, Gemma Ricevuto, Enrico Fiorentini, Giammaria Sarti, Donatella Mackay, Andrew Reay Int J Mol Sci Article Merkel cell carcinomas (MCCs) are rare, aggressive, cutaneous neuroendocrine tumours, approximately 80% of which are caused by the genomic integration of Merkel cell polyomavirus (MCPyV). MCPyV-positive MCCs carry poor prognosis in approximately 70% of cases, highlighting the need for greater understanding of the oncogenic mechanisms involved in pathogenesis, progression and post-therapeutic relapse, and translation into novel therapeutic strategies. In a previous pilot study, we reported a potential relationship between MCPyV gene expression and oncogenic alternative Δ exon 6–7 TrkAIII splicing in formalin-fixed paraffin-embedded (FFPE) MCC tissues from a 12-patient cohort of >90% MCPyV-positive MCCs, diagnosed at San Salvatore Hospital, L’Aquila, Italy, characterising a new MCC subgroup and unveiling a novel potential MCPyV oncogenic mechanism and therapeutic target. This, however, could not be fully verified due to poor RNA quality and difficulty in protein extraction from FFPE tissues. Here, therefore, we extend our previous observations to confirm the relationship between MCPyV and oncogenic alternative Δ exon 6–7 TrkAIII splicing in fresh, nonfixed, MCPyV-positive MCC metastasis by detecting sequence-verified RT-PCR products, including full-length Δ exon 6–7 TrkAIII, and by Western blot detection of a 100 kDa TrkA protein isoform of identical size to 100 kDa Δ exon 6–7 TrkAIII expressed by stable transfected SH-SY5Y cells. We also report that in three MCC patients submitted for multidisciplinary treatment, including locoregional chemotherapy, MCPyV large T-antigen mRNA expression, Δ exon 6–7 TrkAIII mRNA expression and intracellular indirect immunofluorescence (IF) TrkA and phosphorylation protein isoform(s) immunoreactivity in FFPE tissues were not reduced in postchemotherapeutic-relapsed MCCs compared to pretherapeutic MCCs, extending the possible roles of this novel potential MCPyV oncogenic mechanism from MCC pathogenesis to post-therapeutic relapse and progression. Detection of alternative Δ exon 6–7 TrkAIII splicing in MCC, therefore, not only characterises a new MCPyV-positive MCC subgroup and unveils a novel potential MCPyV oncogenic mechanism but also identifies patients who may benefit from inhibitors of MCPyV T-antigen and/or TrkAIII expression or clinically approved Trk kinase inhibitors such as larotrectinib or entrectinib, which are known to inhibit activated TrkA oncogenes and to elicit durable responses in TrkA-fusion oncogene-driven cancers, supporting the call for a large-scale multicentre clinical study. MDPI 2020-11-03 /pmc/articles/PMC7662965/ /pubmed/33153070 http://dx.doi.org/10.3390/ijms21218222 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guadagni, Stefano
Farina, Antonietta Rosella
Cappabianca, Lucia Annamaria
Sebastiano, Michela
Maccarone, Rita
Zelli, Veronica
Clementi, Marco
Chiominto, Alessandro
Bruera, Gemma
Ricevuto, Enrico
Fiorentini, Giammaria
Sarti, Donatella
Mackay, Andrew Reay
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
title Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
title_full Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
title_fullStr Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
title_full_unstemmed Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
title_short Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
title_sort multidisciplinary treatment, including locoregional chemotherapy, for merkel-polyomavirus-positive merkel cell carcinomas: perspectives for patients exhibiting oncogenic alternative δ exon 6–7 trkaiii splicing of neurotrophin receptor tropomyosin-related kinase a
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662965/
https://www.ncbi.nlm.nih.gov/pubmed/33153070
http://dx.doi.org/10.3390/ijms21218222
work_keys_str_mv AT guadagnistefano multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT farinaantoniettarosella multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT cappabiancaluciaannamaria multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT sebastianomichela multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT maccaronerita multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT zelliveronica multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT clementimarco multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT chiomintoalessandro multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT brueragemma multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT ricevutoenrico multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT fiorentinigiammaria multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT sartidonatella multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea
AT mackayandrewreay multidisciplinarytreatmentincludinglocoregionalchemotherapyformerkelpolyomaviruspositivemerkelcellcarcinomasperspectivesforpatientsexhibitingoncogenicalternativedexon67trkaiiisplicingofneurotrophinreceptortropomyosinrelatedkinasea